Biomolecules

Insufficient Institutional Backing is a Leading Cause of Doctor Reluctance in Addressing Addiction
— Lack of Institutional Support and Knowledge rank as Key Factors A recent systematic review of 283 studies has determined that a lack of institutional backing remains the top reason clinicians hesitate to intervene in addiction cases, as highlighted by the findings. In their analysis, Wilson Compton, MD, MPE, deputy director of the National Institute on Drug Abuse (NIDA), and his colleagues reported in JAMA Network Open that 81.2% of the reviewed articles cited the institutional environment as
Insufficient Institutional Backing is a Leading Cause of Doctor Reluctance in Addressing Addiction
226 likes 9 439 views
If CD19 CAR T-Cell Therapy Doesn't Work in Lymphoma, Consider a CD22 Option
— Potential for durable responses with alternative antigen-targeted therapy A promising new treatment targeting a different antigen has shown success among patients with large B-cell lymphoma who previously relapsed after receiving CD19-directed CAR T-cell therapy (CAR19), according to findings from a phase I dose-finding study. In the study, 38 patients who had not responded to CAR19 achieved a 68% overall response rate and a 53% complete response rate following treatment with autologous
If CD19 CAR T-Cell Therapy Doesn't Work in Lymphoma, Consider a CD22 Option
278 likes 10 788 views